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Abstract
A new quassinoid, designated 2′-(R)-O-acetylglaucarubinone (1), and seven known quassinoids
(2–8) were isolated, using bioactivity-guided separation, from the bark of Odyendyea gabonensis
(Pierre) Engler [syn. Quassia gabonensis Pierre (Simaroubaceae)]. The structure of 1 was
determined by spectroscopic analysis, and by semi-synthesis from glaucarubolone. Complete 1H
and 13C NMR assignments of compounds 1–8 were also established from detailed analysis of two-
dimensional NMR spectra, and the reported configurations in odyendene (7) and odyendane (8)
were corrected. Compound 1 showed potent cytotoxicity against multiple cancer cell lines. Further
investigation using various types of breast and ovarian cancer cell lines suggested that 1 does not
target the estrogen receptor (ER) or progesterone receptor (PR). When tested against mammary
epithelial proliferation in vivo using a Brca1/p53-deficient mice model, 1 also caused significant
reduction in mammary duct branching.
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Quassinoids are known as the bitter principles of Simaroubacaeous plants.1–3 They are
highly oxygenated triterpenes and possess a wide spectrum of in vitro and in vivo biological
activities, including antitumor, antimalarial, antiviral, anti-inflammatory, antifeedant,
insecticidal, amoebicidal, anti-ulcer, and herbicidal.1 In particular, the quassinoid bruceantin
was brought to a phase II clinical trial as an anticancer drug candidate;4 however, lack of
significant efficacy in treating human cancer led to termination of its clinical development in
the early 1980’s.5 From the initial studies on various quassinoids, the mechanism of action
was attributed to the inhibition of site-specific protein synthesis by prevention of ribosomal
peptidyl transferase activity leading to termination of chain elongation.6 However, other
postulated mechanisms for inhibition of cancer cell growth include, but are not limited to,
inhibition of plasma membrane NADH oxidase activity,7 down-regulation of c-myc
oncogene,8 and mitochondrial membrane depolarization with caspase-3 activation.9
The stem bark of Odyendyea gabonensis (Pierre) Engler [syn. Quassia gabonensis Pierre
(Simaroubacae)] is a source of quassinoids, and seven quassinoids, 2′-(S)-O-
acetylglaucarubinone (2), glaucarubinone (3), ailanthinone (4), 2′-(R)-O-acetylglaucarubin
(5), excelsin (6), odyendene (7), and odyendane (8), were previously isolated.10–12 We
have re-investigated the stem bark of this plant, due to its potent selective cytotoxicity
against breast cancer cell lines in our prior studies aimed at discovering antitumor agents
from higher plants. Bioactivity-directed fractionation of this plant extract led to the isolation
and characterization of a new quassinoid, 2′-(R)-O-acetylglaucarubinone (1), as an active
principle, along with 2–8. We describe herein the isolation and structure determination of 1
by semisynthesis. The isolated quassinoids were evaluated in vitro against human tumor cell
replication (DU145 prostate cancer, A549 human lung carcinoma, KB human epidermoid
carcinoma of the nasopharynx, and KB-V multi-drug resistant expressing P-glycoprotein).
Compound 1 was also further investigated for in vitro cytotoxic activity against multiple
breast cancer cell lines. We also describe the effect of 1 on mammary epithelial proliferation
in vivo using a Brca1/p53-deficient mice model.
During this investigation, detailed analyses of 1H and 13C NMR spectra of quassinoids (1–8)
were conducted, and led to the revision of some previously reported data of 2–6, as well as
the correction of configurations in odyendene (7) and odyendane (8).12 For the convenience
of comparison and discussion, 2′-acetylglaucarubinone (2) is referred to as 2′-(S)-O-
acetylglaucarubinone and its 2′-epimer (1) as 2′-(R)-O-acetylglaucarubinone.
Results and Discussion
O. gabonensis was collected in Gabon in 1991 by NCI. The active MeOH/CH2Cl2 (1/1)
extract of the bark was fractionated into hexane- and EtOAc-soluble fractions, as well as
insoluble residue. The active EtOAc-soluble fraction was subjected to silica gel column
chromatography (CC), (hexane:EtOAc gradient, then MeOH), followed by reverse phase
HPLC to give the new compound 1 and the known quassinoids, 2–8.
Compound 1 was isolated as a colorless, amorphous solid, and its HREIMS indicated a
molecular formula of C27H36O11, which was identical with that of 2. The close similarity in
the 1H and 13C NMR spectra (Tables 1 and 2, respectively) of 1 and 2, including coupling
patterns, implied that 1 was an epimer of 2. The only spectroscopic differences were in the
chemical shifts of signals relative to the side chain at C-15, which indicated that 1 could be
2′-epi-acetoxygalucarubinone.
Due to the small amount of 1 isolated from the plant, as well as the limited supply of the
original plant material, the C-2′ epimer of 2 was synthesized from glaucarubolone (10) to
identify the structure and configuration of 1. According to Valeriote’s procedure,13 all four
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hydroxy groups of 10 were protected as trimethylsilyl (TMS) ethers (Scheme 1). The
resulting fully protected tetra-O-trimethylsilyl glaucarubolone was carefully treated with
tetra-n-butylammonium fluoride to selectively remove the C-12 and C-15 TMS groups and
provide 11 in 86% yield. Condensation of 11 with 13, which was derived from acetylation of
(R)-2-hydroxy-2-methyl butyric acid with acetyl chloride, provided 14 in 77% yield, based
on the recovery of 11. The remaining TMS groups were removed with citric acid to afford 1
in 76% yield.
The equivalence of synthetic 1 and the natural product was confirmed by comparing their 1H
and 13C NMR spectra (Tables 1 and 2). Additional HPLC analysis also supported the
structure of naturally occurring 1 as 2′-(R)-O-acetylglaucarubinone. Both natural and
synthetic 1 had a retention time of 15.6 min, while 2′-(S)-O-acetylglaucarubinone (2) had a
retention time of 14.2 min.14
Compounds 2 and 3, were identified as 2′-acetylglaucarubinone [2′-(S)-O-
acetylglaucarubinone] and glaucarubinone, respectively, by comparing their physical and
spectroscopic data (IR, MS, 1H and 13C NMR) with those reported previously in the
literature.11 The configuration of the asymmetric carbon atom at C-2′ in the side chain of
glaucarubinone (3) has been assigned as S, on the basis of an enantio-selective total
synthesis.15 In addition, it has been reported that complete acetylation of 3 afforded 9.16
Thus, 2 was acetylated to yield its tetra-acetate (Scheme 2), which was identified as
tetracetylglaucarubinone (9) by comparison with the spectroscopic data described in the
literature. Thus, the absolute configuration of 2 at C-2′ was established as S.
Because 1H and 13C NMR spectroscopic data of 4–6 in the literature are incomplete or
absent, we also established the complete assignment of 1H and 13C NMR resonances of
these three compounds using a combination of two-dimensional (2D) NMR techniques. Our
spectroscopic data are shown in Tables 1 and 2.
Quassinoids 7 and 8 were identified as odyendene and odyendane, respectively;12 however;
detailed NMR spectroscopic analyses using 1D and 2D NMR techniques revealed that the
previously reported α-orientations at C-2 and C-11 were incorrect. In the 1H NMR spectrum
of 8, the coupling patterns of H-2 (δH 4.44, dd, J1 = 11.3, J2 = 6.0) and H-11 (δH 3.62, td, J1
= 9.8, J2 = 3.9) clearly indicated β-axial orientations. NOE effects observed between H-2
and β-methyl groups at C-19 and C-28, as well as between H-11 and β-methyl groups at
C-19 and C-30, indicated β-configurations for the methoxy groups at C-2 and C-11.
Accordingly, we consider the structures of 7 and 8 in the literature to constitute a prima
facie case of inadvertently misdrawn configurations at C-2 and C-11. The structures of 7 and
8 are presented herein with the correct configurations.
Biological Activity
Quassinoids 2–4 were previously reported to be moderately cytotoxic against the KB cancer
cell line.17–19 Therefore, quassinoids 1–6 were tested for in vitro cytotoxic activity against
KB and three additional human cancer cell lines. The results are summarized in Table 3.
Quassinoids 1, 2, and 4 showed the highest potency, with EC50 values ranging from 0.04 to
0.18 µM against DU145, A549, and KB cell lines, and 0.37 to 0.44 µM against KB-VIN.
Compounds 3 and 5 showed significant, but lower, cytotoxicity.
The synthesized 1 was further tested against multiple breast cancer cell lines, including
MDA-MB-231 [estrogen receptor negative (ER−) basal-like breast cancer], MDA-MB-468,
MCF-7, MCF/HER2 [MCF-7 over-expressing HER2], SKBR3 (ER-, HER2 over-expressing
luminal-like breast cancer) and BT474 [ER− and progesterone receptor (PR)-positive], as
well as ovarian cancer cell lines, including MSPC1, 2774-C10 (ovarian cancer expressing
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normal level of HER2), HeyA8 (highly metastatic epithelial ovarian) and Hoc7 (human
ovarian adenocarsinoma). As shown in Figure 1, compound 1 greatly suppressed tumor cell
growth of MCF7/HER2, SKBR3, as well as triple negative MDA-MB468, and MDA-
MB-231 breast cancer cell lines. The efficient suppression of growth of ER-negative MDA-
MB468 and MDA-MB-231 cell lines implies that ER and PR may not be major targets of 1.
This is also supported by the observation of low sensitivity of BT474 and MCF7 to 1. On
the other hand, HER2-overexpressing ER/PR-negative SKBR3 cells, showed
hypersensitivity to compound 1, suggesting that 1 might interfere with the HER2 signaling
pathways. This view was also supported by the higher sensitivity of MCF-/HER2 compared
to MCF-7. However, targets and mechanisms of action of 1 required further studies.
Compound 1 also demonstrated significant inhibition of ovarian cancer cell lines, MSPC1,
2774-C10, HeyA8 and Hoc7 (Figure 2). Taken together, these results led us to assess the
effect of 1 on mammary epithelial proliferation in vivo using a Brca1/p53-deficient mice
model.
The human tumor suppressor gene BRCA1 interacts directly with ER and PR, and modulates
the transcription activities of ERα and PR, as well as the nongenomic function of ERα.
Mutations in the BRCA1 gene are associated with an increased risk of breast and ovarian
cancers. Previous studies revealed that mammary epithelial cells from mutant mice express
higher levels of PR and show extensive mammary epithelial proliferation.20,21 We have
used these mutant and wild-type mice to test anti-proliferation effects of
neotanshinlactones22 in vivo, and found that Brca1f11/f11p53f5&6/f5&6Crec mice provide a
sensitive readout. The effect of 1 on mammary epithelial proliferation was compared with
those of paclitaxel and another quassinoid, bruceantin. Paclitaxel is used in clinical
treatment of breast cancer, and bruceantin was evaluated in Phase II clinical trials as an
anticancer drug candidate. In accordance with prior observations, there was extensive side
branching in the mammary glands of vehicle-treated Brca1f11/f11p53f5&6/f5&6Crec mice
(Figure 3A, d & 3B). However, daily peritoneal injection of 0.1 mg of 1 for 7 days reduced
branching points to 32% (Figure 3A, a & 3B) compared with that of vehicle treated mice.
Importantly, the reduction was more pronounced than results with paclitaxel (Figure 3A, b
& 3B) or bruceantin (Figure 3A, c & 1B). Using two-tail t-test, 1 (P = 0.0014), paclitaxel (P
= 0.0016), and bruceantin (P = 0.023) treatment all led to significant reduction in mammary
duct branching. While signaling pathways driving the elevated proliferation in Brca1/p53-
deficient mammary gland are not well characterized, it is interesting to note that the EGFR
pathway was up-regulated in mammary epithelial cells from BRCA1 carriers.23 It is known
that EGFR family members can form heterodimers. Further studies would be needed to
determine whether compound 1 indeed targets the EGFR pathways in the mouse model and
the HER2 pathways in the breast cancer cell lines.
Conclusions
A new quassinoid, 2′-(R)-O-acetylglaucarubinone (1) and seven known quassinoids (2–8)
were isolated from the bark of Odyendyea gabonensis (Pierre) Engler [syn. Quassia
gabonensis Pierre] (Simaroubaceae) using bioactivity-guided separation. The structure of 1
was determined by spectroscopic analysis, and confirmed by semi-synthesis from 10. We
also established the complete assignments of 1H and 13C NMR signals of 4–6, as well as
corrected configurations in 7 and 8. The synthesized 1 showed potent cytotoxic activity
against multiple cancer cell lines. The pattern of cytotoxicity against breast and ovarian
cancer cell lines suggested that 1 does not target ER or PR. Brca1/p53-deficient mice treated
with 1 showed significant reduction in mammary ductal branching, indicating that 1 could
be a promising antitumor lead compound.
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Proton nuclear magnetic resonance (1H NMR) spectra were measured on a Varian Gemini
2000 (300 MHz) or UNITY INOVA-500 (500 MHz) NMR spectrometer. All chemical shifts
are reported in δ (ppm). Mass spectra were obtained on a JEOL JMS-700 (2) mass
spectrometer. IR spectra were measured on a JEOL FT/IR-680 Plus spectrophotometer.
Analytical thin layer chromatography (TLC) was performed on Merck pre-coated aluminum
silica gel sheets (Kieselgel 60 F 254). HPLC experiments were performed by using a
Shimazu LC-10 or LC-6 with UV detection at 254, 240, or 210 nm. An Alltech C18 column
(22 mm diameter × 250 mm) or YMC C18 column (46 mm diameter × 250 mm) was used in
RP-HPLC.
Plant Collection and Extract Preparation
Bark of Odyendyea gabonensis was collected in Gabon on February 6, 1991. The bark was
extracted with MeOH/CH2Cl2 (1/1).
Isolation of Quassinoids
The raw extract (QG; 9.9 g) (ED50 against MCF-7 <2.5 µg/mL) was separated into a
hexane-soluble fraction (QGP; 475 mg), an EtOAc-soluble fraction (QGE; 4.28 g), and
residue (QGIn). Then, the EtOAc fraction (ED50 <0.37 mg/mL) was separated by silica gel
CC (eluent: hexane:EtOAc = 4:1−2:1−1:1 to MeOH) to afford fractions QGE-S8 (110 mg)
and QGE-S9 (1.4 g). Fraction QGE-S9 was separated by silica gel CC (eluent:
MeOH:CHCl3 gradient) to afford fractions QGE-S9-4 (12 mg), QGE-S9-5 (414 mg), QGE-
S9-6 (32 mg), QGE-S9-7 (259 mg) and QGE-S9-11 (41 mg). QGE-S9-6 was applied to RP-
HPLC (column: YMC C18; eluent: MeOH:H2O = 6:4; flow rate: 3 mL/min) to afford 2 (7.5
mg). QGE-S8, QGE-S9-5, and QGE-S9-7 were combined (784 mg) and applied to silica gel
CC (eluent: 8% MeOH:CHCl3) to give fractions QGE-S9-5-3 (284 mg) and QGE-S9-5-4
(163.5 mg). A portion of QGE-S9-5-3 (144.6 mg) was applied to RP-HPLC (column: YMC
C18; eluent: MeOH:H2O = 6:4; flow rate: 3 mL/min) to afford 2 (36.6 mg) and 4 (15.1 mg).
The remainder (110 mg) was subjected to RP-HPLC (column: Alltima C18; eluent:
CH3CN:H2O gradient; flow rate; 5 mL/min) to give 1 (5.0 mg). QGE-S9-5-4 was separated
by HPLC (column: Alltima C18; eluent: CH3CN:H2O gradient; flow rate: 5 mL/min) to give
3 (11.5 mg). QGE-S9-11 was applied to RP-HPLC (column: YMC C18; eluent: MeOH:H2O
= 6:4 ; flow rate: 3 mL/min) to give 5 (16.8 mg) and 6 (3.1 mg). QGE-S9-4 was separated
by preparative TLC (eluent: 5% MeOH:CH2Cl2) to afford 7 (9.5 mg) and 8 (2.5 mg).
2′-(R)-Acetylglaucarubinone (1)
IR (liquid film) νmax 3447 (OH), 1741 (C=O), 1636 (C=C) cm−1; 1H NMR, see Table 1; 13C
NMR see Table 2); HREIMS m/z 536.2258 [M]+ (calcd for C27H36O11 536.2260).
Acetylation of 2′-(S)-Acetylglaucarubinone (2)
Acetic anhydride (0.1 mL) was added to a pyridine solution (0.5 mL) of 2 (9.3 mg), and the
reaction mixture was stirred at rt overnight, then extracted with EtOAc/water. The organic
layer was dried over anhydrous Na2SO4, filtered, and evaporated to give a residue, which
was then purified by silica gel CC (eluent; EtOAc:hexane = 1:10) to afford pure 9 (4.1 mg).
Semi-synthesis of 2′-(R)-Acetylglaucarubinone (1) from Glaucarubolone (10)
TMSOTf (0.15 mL, 0.75 mmol) was added to a solution of 10 (50 mg, 0.13 mmol) in
pyridine (1.3 mL) and Et3N (0.21 mL, 1.5 mmol) at 0 °C. After stirring for 2.5 h at rt, the
mixture was cooled to 0 °C, and a 1.0 M TBAF in THF solution (0.52 mL, 0.52 mmol) was
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added dropwise. The mixture was warmed to rt over 1 h, diluted with water, and extracted
with EtOAc. The organic phase was washed with brine, dried over Na2SO4, and
concentrated. The residue was chromatographed on silica gel eluting with EtOAc:hexane
(1:4) to obtain di-TMS ether 11 (60 mg, 0.11 mmol, 86%), which was dissolved in CH2Cl2
(2.5 mL). EDCI (150 mg, 0.78 mmol), DMAP (27 mg, 0.22 mmol) and 13 (110 mg, 0.68
mmol) were added to the solution, which was stirred at rt overnight. The mixture was
partitioned between water and CH2Cl2. The organic phase was washed with brine, dried
over Na2SO4, and concentrated. The residue was chromatographed on silica gel eluting with
EtOAc:hexane (1:4) to give ester 14 (26 mg, 0.04 mmol, 35%) along with 11 (32 mg, 53%).
A solution of 14 (24 mg, 0.035 mmol) in MeOH (1.0 mL) was treated with citric acid (25
mg, 0.13 mmol) at rt for 2.5 h. After addition of EtOAc, the mixture was filtered through
SiO2. The SiO2 was washed with EtOAc, and the combined filtrates were concentrated. The
residue was chromatographed on silica gel eluting with EtOAc:hexane (1:4) to give 1 (14
mg, 0.026 mmol, 75%).
Brca1fp/fpp53fp/fpCre Mutant Mice
Generation of Brca1fp/fpp53fp/fpCre and p53fp/fpCre mice has been described previously.
17,18 The mice were in a C57BL/6 and 129/Sv, mixed background. All animal experiments
were in accordance with guidelines of the Federal and Institutional Animal Care and Use
Committee at the University of California, Irvine.
Treatment with 2’-(R)-Acetylglaucarubinone (1)
Three-month-old mice were treated with 0.1 mg of 1 or vehicle daily for 7 days. Stock
solution was 1 mg/mL in dimethylsulfoxide (DMSO). A mixture of 10 µL of stock solution,
30 µL of 40% polyethylene glycol (PEG), and 60 µL of 0.9% NaCl solution was prepared at
the time of treatment. Vehicles include DMSO, PEF and NaCl solution. Vehicle or
compound was administered i.p. every day as described.
Histology and Immunohistochemistry
The fourth pair glands were dissected and spread on a glass slide. After fixation with
Carnoy’s fixative for 3 h, the tissues were hydrated and stained in Carmine alum overnight
as described at http://mammary.nih.gov/tools/histological/Histology/index.html#a1.
Branching points in three random areas totaling approximately 2 mm2 were counted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Cytotoxicity of 1 against multiple breast cancer cell lines. The table lists the protein
expression status of ER/PR, HER2 over-expression, and wild-type (WR) or mutant (M)
TP53 of each cell line.24
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Cytotoxicity of 1 against multiple ovarian cancer cell lines.
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Treatment with 1 leads to decreased mammary ductal branching. Mammary gland whole
mounts were prepared from Brca1f11/f11p53f5&6/f5&6Crec mice following treatment with 0.1
mg of 1 and paclitaxel daily for 7 days and bruceantin daily for 5 days. (A) Mammary gland
whole mounts of 1 (a), paclitaxel (b), bruceantin (c), and vehicle (d)-treated 3-month-old
mice. (B) Number of branching points in the mammary glands of treated mice. The data
represents average of branch points in three randomly selected areas ± SD. (* P ≤ 0.02; ** P
≤ 0.001)
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Reagents and conditions, a) TMSOTf, Et3N, Py, rt, 2.5 h then TBAF, rt, 1 h; b) AcCl, rt, 2.5
h; c) 13, EDCl, DMAP, CH2Cl2, rt, 3 d; d) citric acid, MeOH, rt, 2.5 h
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Table 3
Cytotoxic Activity of Quassinoids 1–6
ED50 (µM)a
compound DU145 A549 KB KB-VIN
1 0.04 0.06 0.05 0.42
2 0.07 0.07 0.07 0.44
3 0.47 0.88 0.44 1.24
4 0.09 0.13 0.18 0.37
5 0.83 3.6 0.67 NAb
6 4.7 16 4.3 NA
paclitaxel 0.003 0.008 0.007 >1
a
Values are the mean ED50 (concentrations that gave 50% effect under the defined assay condition) in µM.
b
Tested compounds did no reach 50% inhibition at 10 µg/mL.
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